Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: DexCom or Abbott Labs?

TheMotleyFool

0 0

When it comes to relatively stable healthcare growth stocks, DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) just might fit the bill. Worth around $61 billion, the continuous glucose monitor (CGM) specialist DexCom is small compared to medical device giant Abbott's market cap of $228 billion -- and it's no wonder why, because Abbott makes everything from CGMs to COVID tests and even surgical tools.

Still, both companies are profitable and growing at a steady clip, and neither faces any obvious obstacles to their continued success. To figure out which of the pair is a better stock to buy today, let's investigate one perspective on each.

Image source: Getty Images.

Source Fool.com

Like: 0

ABT

Share